KR20250005182A - 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민 - Google Patents
인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민 Download PDFInfo
- Publication number
- KR20250005182A KR20250005182A KR1020247035759A KR20247035759A KR20250005182A KR 20250005182 A KR20250005182 A KR 20250005182A KR 1020247035759 A KR1020247035759 A KR 1020247035759A KR 20247035759 A KR20247035759 A KR 20247035759A KR 20250005182 A KR20250005182 A KR 20250005182A
- Authority
- KR
- South Korea
- Prior art keywords
- dmt
- meo
- pharmaceutically acceptable
- acceptable salt
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000085.5 | 2022-03-27 | ||
| EP22000085 | 2022-03-27 | ||
| EP22000084.8 | 2022-03-27 | ||
| EP22000084 | 2022-03-27 | ||
| EP23153996 | 2023-01-30 | ||
| EP23154014 | 2023-01-30 | ||
| EP23154014.7 | 2023-01-30 | ||
| EP23153996.6 | 2023-01-30 | ||
| PCT/EP2023/057871 WO2023186824A1 (en) | 2022-03-27 | 2023-03-27 | 5-methoxy-n,n-dimethyltryptamine for the treatment of cognitive dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250005182A true KR20250005182A (ko) | 2025-01-09 |
Family
ID=86007029
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247035759A Pending KR20250005182A (ko) | 2022-03-27 | 2023-03-27 | 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민 |
| KR1020247035654A Pending KR20240167878A (ko) | 2022-03-27 | 2023-03-27 | 정신운동지연의 치료를 위한 5-메톡시-n,n-디메틸트립타민 |
| KR1020247035763A Pending KR20250005184A (ko) | 2022-03-27 | 2023-03-27 | 사회적/감정적 위축 또는 분리의 치료를 위한 5-메톡시-n,n-다이메틸트립타민 |
| KR1020247035657A Pending KR20250005173A (ko) | 2022-03-27 | 2023-03-27 | 산후 우울증의 치료 |
| KR1020247035707A Pending KR20250005175A (ko) | 2022-03-27 | 2023-03-27 | 양극성 장애의 치료를 위한 5-meo-dtm |
| KR1020247035719A Pending KR20250005177A (ko) | 2022-03-27 | 2023-03-27 | 불안 치료를 위한 5-메톡시-n,n-다이메틸트립타민 |
| KR1020247035720A Pending KR20250005178A (ko) | 2022-03-27 | 2023-03-27 | 수면 장애의 치료에 사용하기 위한 5-meo-dmt |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247035654A Pending KR20240167878A (ko) | 2022-03-27 | 2023-03-27 | 정신운동지연의 치료를 위한 5-메톡시-n,n-디메틸트립타민 |
| KR1020247035763A Pending KR20250005184A (ko) | 2022-03-27 | 2023-03-27 | 사회적/감정적 위축 또는 분리의 치료를 위한 5-메톡시-n,n-다이메틸트립타민 |
| KR1020247035657A Pending KR20250005173A (ko) | 2022-03-27 | 2023-03-27 | 산후 우울증의 치료 |
| KR1020247035707A Pending KR20250005175A (ko) | 2022-03-27 | 2023-03-27 | 양극성 장애의 치료를 위한 5-meo-dtm |
| KR1020247035719A Pending KR20250005177A (ko) | 2022-03-27 | 2023-03-27 | 불안 치료를 위한 5-메톡시-n,n-다이메틸트립타민 |
| KR1020247035720A Pending KR20250005178A (ko) | 2022-03-27 | 2023-03-27 | 수면 장애의 치료에 사용하기 위한 5-meo-dmt |
Country Status (9)
| Country | Link |
|---|---|
| US (10) | US20250235427A1 (cg-RX-API-DMAC7.html) |
| EP (8) | EP4499085A1 (cg-RX-API-DMAC7.html) |
| JP (7) | JP2025510294A (cg-RX-API-DMAC7.html) |
| KR (7) | KR20250005182A (cg-RX-API-DMAC7.html) |
| CN (5) | CN119546298A (cg-RX-API-DMAC7.html) |
| AU (7) | AU2023244447A1 (cg-RX-API-DMAC7.html) |
| CA (7) | CA3255652A1 (cg-RX-API-DMAC7.html) |
| IL (7) | IL315895A (cg-RX-API-DMAC7.html) |
| WO (9) | WO2023186832A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| EP3868364A1 (en) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| HUE066828T2 (hu) | 2019-02-22 | 2024-09-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére |
| DK3927338T3 (da) * | 2019-02-22 | 2025-01-06 | Gh Res Ireland Limited | Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser |
| KR20220008824A (ko) * | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| US20230157981A1 (en) * | 2020-04-20 | 2023-05-25 | Lobe Sciences Ltd. | Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022189662A1 (en) * | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
| CA3216889A1 (en) * | 2021-04-26 | 2022-11-03 | Glenn Short | Novel n,n-dimethyltryptamine compositions and methods |
| WO2023028086A1 (en) * | 2021-08-23 | 2023-03-02 | Gilgamesh Pharmaceuticals, Inc. | Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists |
| AU2022413759A1 (en) * | 2021-12-13 | 2024-06-27 | Beckley Psytech Limited | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
-
2023
- 2023-03-27 KR KR1020247035759A patent/KR20250005182A/ko active Pending
- 2023-03-27 US US18/851,301 patent/US20250235427A1/en active Pending
- 2023-03-27 KR KR1020247035654A patent/KR20240167878A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057879 patent/WO2023186832A1/en not_active Ceased
- 2023-03-27 CA CA3255652A patent/CA3255652A1/en active Pending
- 2023-03-27 US US18/851,316 patent/US20250213530A1/en not_active Abandoned
- 2023-03-27 WO PCT/EP2023/057828 patent/WO2023186798A1/en not_active Ceased
- 2023-03-27 JP JP2024557206A patent/JP2025510294A/ja active Pending
- 2023-03-27 IL IL315895A patent/IL315895A/en unknown
- 2023-03-27 IL IL315903A patent/IL315903A/en unknown
- 2023-03-27 CA CA3255338A patent/CA3255338A1/en active Pending
- 2023-03-27 EP EP23717045.1A patent/EP4499085A1/en active Pending
- 2023-03-27 US US18/851,362 patent/US20250213534A1/en active Pending
- 2023-03-27 EP EP23717044.4A patent/EP4499084A1/en active Pending
- 2023-03-27 US US18/851,329 patent/US20250170099A1/en active Pending
- 2023-03-27 JP JP2024557207A patent/JP2025510295A/ja active Pending
- 2023-03-27 IL IL315904A patent/IL315904A/en unknown
- 2023-03-27 CA CA3255654A patent/CA3255654A1/en active Pending
- 2023-03-27 CN CN202380036934.8A patent/CN119546298A/zh active Pending
- 2023-03-27 AU AU2023244447A patent/AU2023244447A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057875 patent/WO2023186828A1/en not_active Ceased
- 2023-03-27 US US18/851,294 patent/US20250213528A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057874 patent/WO2023186827A1/en not_active Ceased
- 2023-03-27 CN CN202380042750.2A patent/CN119255799A/zh active Pending
- 2023-03-27 JP JP2024557197A patent/JP2025510913A/ja active Pending
- 2023-03-27 CN CN202380042391.0A patent/CN119255798A/zh active Pending
- 2023-03-27 US US18/851,311 patent/US20250213529A1/en active Pending
- 2023-03-27 JP JP2024557761A patent/JP2025511084A/ja active Pending
- 2023-03-27 WO PCT/EP2023/057885 patent/WO2023186837A1/en not_active Ceased
- 2023-03-27 JP JP2024557199A patent/JP2025510914A/ja active Pending
- 2023-03-27 EP EP23717041.0A patent/EP4499081A1/en not_active Withdrawn
- 2023-03-27 AU AU2023246681A patent/AU2023246681A1/en active Pending
- 2023-03-27 KR KR1020247035763A patent/KR20250005184A/ko active Pending
- 2023-03-27 JP JP2024557208A patent/JP2025510296A/ja active Pending
- 2023-03-27 AU AU2023244449A patent/AU2023244449A1/en active Pending
- 2023-03-27 US US18/851,336 patent/US20250213531A1/en active Pending
- 2023-03-27 AU AU2023246548A patent/AU2023246548A1/en active Pending
- 2023-03-27 CA CA3255329A patent/CA3255329A1/en active Pending
- 2023-03-27 IL IL315901A patent/IL315901A/en unknown
- 2023-03-27 IL IL315905A patent/IL315905A/en unknown
- 2023-03-27 KR KR1020247035657A patent/KR20250005173A/ko active Pending
- 2023-03-27 IL IL315900A patent/IL315900A/en unknown
- 2023-03-27 AU AU2023242439A patent/AU2023242439A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057868 patent/WO2023186821A1/en not_active Ceased
- 2023-03-27 KR KR1020247035707A patent/KR20250005175A/ko active Pending
- 2023-03-27 EP EP23717032.9A patent/EP4499072A1/en active Pending
- 2023-03-27 US US18/851,349 patent/US20250213533A1/en active Pending
- 2023-03-27 CN CN202380037532.XA patent/CN119278036A/zh active Pending
- 2023-03-27 EP EP23717034.5A patent/EP4499074A1/en active Pending
- 2023-03-27 EP EP23717038.6A patent/EP4499078A1/en active Pending
- 2023-03-27 KR KR1020247035719A patent/KR20250005177A/ko active Pending
- 2023-03-27 CA CA3255511A patent/CA3255511A1/en active Pending
- 2023-03-27 JP JP2024557757A patent/JP2025512866A/ja active Pending
- 2023-03-27 CN CN202380035882.2A patent/CN119156212A/zh active Pending
- 2023-03-27 EP EP23717413.1A patent/EP4499089A1/en active Pending
- 2023-03-27 CA CA3255640A patent/CA3255640A1/en active Pending
- 2023-03-27 CA CA3255709A patent/CA3255709A1/en active Pending
- 2023-03-27 EP EP23717037.8A patent/EP4499077A1/en not_active Withdrawn
- 2023-03-27 AU AU2023246773A patent/AU2023246773A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057871 patent/WO2023186824A1/en not_active Ceased
- 2023-03-27 KR KR1020247035720A patent/KR20250005178A/ko active Pending
- 2023-03-27 IL IL315892A patent/IL315892A/en unknown
- 2023-03-27 WO PCT/EP2023/057878 patent/WO2023186831A1/en not_active Ceased
- 2023-03-27 WO PCT/EP2023/057845 patent/WO2023186808A1/en not_active Ceased
- 2023-03-27 AU AU2023244453A patent/AU2023244453A1/en active Pending
- 2023-09-27 US US18/373,904 patent/US20240115549A1/en active Pending
- 2023-09-27 US US18/373,914 patent/US20240115550A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4499078A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of cognitive dysfunction | |
| KR20250005181A (ko) | 인지 기능장애 치료 | |
| KR20250138805A (ko) | 정신 장애의 치료 | |
| KR20250139377A (ko) | 수유부의 정신 장애 치료에 사용하기 위한 5-메톡시-n,n-다이메틸트립타민 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |